Metabolic Peptides
Survodutide 2026: SYNCHRONIZE-2 Phase 3 Results, Dosage, Liver Data & Comparison to Retatrutide
Michael Court
October 1, 2026
6 min read
Boehringer's survodutide posted up to 13.1% weight loss in SYNCHRONIZE-2 today. Every Phase 3 number so far, trial doses, liver data, safety and how it compares.